JRSM > Volume 100, Number 7 > Pp. 326-329

This Article Figures Only Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kroese, M. Articles by Pinder, S. E Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Review

HER2 status in breast cancer—an example of pharmacogenetic testing

Mark Kroese¹ Ron L Zimmern²   Sarah E Pinder³

¹ Consultant in Public Health Medicine, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
² Director, Public Health Genetics Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
³ Consultant Breast Pathologist, Histopathology Department, Addenbrooke's NHS Trust, UK

Correspondence to: Mark Kroese Email address: mark.kroese{at}srl.cam.ac.uk

SUMMARY

The development of new drugs and associated pharmacogenetic tests will provide an increasing number of challenges to health care systems. In particular, how to evaluate their benefits, prioritize for commissioning purposes and implement a service to provide them in a timely manner. This paper presents an overview of HER2 testing for trastuzumab (Herceptin) treatment in breast cancer cases. Immunohistochemistry and fluorescence in situ hybridization laboratory techniques are described and their HER2 testing performances are compared. Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Kumar, R. Afeyan, H.-D. Kim, and D. A. Lauffenburger Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells Mol. Pharmacol., June 1, 2008; 73(6): 1668 - 1678. [Abstract] [Full Text] [PDF]